文献速递青光眼

小梁切除术中单独使用丝裂霉素C或联合前房内贝伐珠单抗:两年比较研究

Trabeculectomy with mitomycin C alone or coupled with intracamerular bevacizumab? A 2-year comparative study.
PubMed 文献 · Br J Ophthalmol · 2021-04-30

这项回顾性两中心比较研究纳入110眼开角型青光眼,比较单独使用丝裂霉素C(MMC)与MMC联合前房内贝伐珠单抗的初次小梁切除术。两组术后24个月眼压均显著降低,联合组在多个绝对成功率靶目标上更高,93%联合组患者无需降眼压药物,并发症低且相似。

要点

  • MMC联合前房内贝伐珠单抗可提高绝对成功率,尤其在低眼压靶目标(≤14、≤16、≤18 mmHg)。
  • 联合组93%患者24个月时无需降眼压药物,41%眼压低于10 mmHg。
  • 两组并发症发生率低且相似,无全身不良事件。

核心结论

  • 在MMC增强的初次小梁切除术中加用前房内贝伐珠单抗可增加获得低眼压结果的机会。

研究设计与样本

  • 回顾性、队列、两中心比较研究,筛查2015年10月至2019年3月患者数据,要求至少24个月随访,共纳入110眼。

主要发现

  • MMC组基线眼压24.4(8.0)mmHg降至术后2年12.1(5.3)mmHg(p<0.001)。
  • MMC+贝伐珠单抗组基线眼压25.1(8.7)mmHg降至术后2年10.8(3.8)mmHg(p<0.001)。
  • 联合组在眼压≤14、≤16、≤18 mmHg的绝对成功率均显著更高(p=0.010、p=0.039、p=0.007)。
  • 联合组93%患者24个月时无需降眼压药物,41%眼压低于10 mmHg。
  • 两组并发症发生率低且相似,无全身不良事件。

关键数值与推荐

  • 手术成功定义为达到不同最大眼压靶目标(≤18、≤16、≤14 mmHg)且眼压降低至少30%且高于5 mmHg。
  • 绝对成功为无需降眼压药物,否则为条件成功。

临床怎么用

  • 对于计划将目标眼压设定在十几mmHg低值的初次小梁切除术,可考虑联合前房内贝伐珠单抗以提高低眼压达成机会。

局限性

  • 回顾性设计可能引入选择偏倚,且为两中心比较研究,结果需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare outcomes of primary trabeculectomy using either mitomycin C (MMC) alone versus MMC augmented with intracamerular bevacizumab in patients with open-angle glaucoma. METHODS: Retrospective, cohort, two-centre, comparative study. Patients' data were screened between October 2015 and March 2019, with inclusion requiring a minimum follow-up of 24 months. Primary outcome was intraocular pressure (IOP) lowering at 24 months, with surgical success defined with different maximum IOP targets (≤18, ≤16 and ≤14 mm Hg) and at least 30% reduction and higher than 5 mm Hg. Absolute success was achieved if no IOP-lowering medication was needed and a qualified success if otherwise. Safety outcomes were analysed. RESULTS: A total of 110 eyes underwent trabeculectomy with MMC, 51 of these combined with intracamerular bevacizumab. Both strategies were effective in terms of IOP lowering (baseline vs 2 years postoperatively: 24.4 (8.0) mm Hg vs 12.1 (5.3) mm Hg in the MMC group; 25.1 (8.7) vs 10.8 (3.8) mm Hg in the MMC+bevacizumab group; p<0.001 in both comparisons). The MMC+bevacizumab group had a significant difference towards higher efficacy on absolute success rates at all targets (IOP≤14 or ≤16 or ≤18 mm Hg; p=0.010, p=0.039 and p=0.007, respectively). The large majority (93%) of the MMC+bevacizumab group was drop-free at 24 months, and 41% had IOP below 10 mm Hg. Complication rates were low and similar between groups, with no systemic adverse events. CONCLUSIONS: Intracamerular bevacizumab in MMC-augmented primary trabeculectomy increases the chances of obtaining low IOP outcomes. This strategy may be useful when planning for surgeries aiming at target pressures in the low teens. TRIAL REGISTRATION NUMBER: ISRCTN93098069.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. José P, Teixeira FJ, Barão R, et al. Trabeculectomy with mitomycin C alone or coupled with intracamerular bevacizumab? A 2-year comparative study. Br J Ophthalmol. 2021. PMID: 33931389. doi:10.1136/bjophthalmol-2021-319039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。